Possible Association Between Dopamine Antagonists and Increased Conversion to Exudative Age-Related Macular Degeneration.

IF 0.5 Q4 OPHTHALMOLOGY
Peter J Weng, Richard Morgan, Dilraj S Grewal, Sharon Fekrat
{"title":"Possible Association Between Dopamine Antagonists and Increased Conversion to Exudative Age-Related Macular Degeneration.","authors":"Peter J Weng, Richard Morgan, Dilraj S Grewal, Sharon Fekrat","doi":"10.1177/24741264251330338","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To investigate whether modulating dopamine signaling affects conversion to exudative age-related macular degeneration (AMD). <b>Methods:</b> A retrospective cohort study was performed using the Duke Epic database. Eyes from patients with a diagnosis of nonexudative AMD with at least 1 year of follow-up were evaluated for conversion to exudative AMD. Eyes with an AMD diagnosis were evaluated for age, sex, smoking history, hypertension, Age-Related Eye Disease Study (AREDS) or AREDS2 prescription, dopamine-modulating therapy prescription, and indication for dopamine-modulating therapy. Generalized estimating equations were used to calculate odds ratios for individual variables on conversion from nonexudative to exudative AMD. <b>Results:</b> Five hundred fifty-eight eyes of 354 patients with an initial diagnosis of nonexudative AMD were evaluated for conversion to exudative AMD. Conversion to exudative AMD was significantly higher in patients who had been on dopamine antagonist therapies for at least 3 years than in patients who were not on any dopamine-modulating therapies. After controlling for other variables, dopamine antagonists were associated with an increased risk for conversion to exudative AMD at 3 years of follow-up (<i>P</i> = .005). <b>Conclusions:</b> These findings suggest that antagonizing dopamine signaling may be associated with the development of macular neovascularization in eyes with nonexudative AMD. Although the data are observational, these findings warrant further investigation of dopamine signaling in conversion to exudative AMD.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330338"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966630/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264251330338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To investigate whether modulating dopamine signaling affects conversion to exudative age-related macular degeneration (AMD). Methods: A retrospective cohort study was performed using the Duke Epic database. Eyes from patients with a diagnosis of nonexudative AMD with at least 1 year of follow-up were evaluated for conversion to exudative AMD. Eyes with an AMD diagnosis were evaluated for age, sex, smoking history, hypertension, Age-Related Eye Disease Study (AREDS) or AREDS2 prescription, dopamine-modulating therapy prescription, and indication for dopamine-modulating therapy. Generalized estimating equations were used to calculate odds ratios for individual variables on conversion from nonexudative to exudative AMD. Results: Five hundred fifty-eight eyes of 354 patients with an initial diagnosis of nonexudative AMD were evaluated for conversion to exudative AMD. Conversion to exudative AMD was significantly higher in patients who had been on dopamine antagonist therapies for at least 3 years than in patients who were not on any dopamine-modulating therapies. After controlling for other variables, dopamine antagonists were associated with an increased risk for conversion to exudative AMD at 3 years of follow-up (P = .005). Conclusions: These findings suggest that antagonizing dopamine signaling may be associated with the development of macular neovascularization in eyes with nonexudative AMD. Although the data are observational, these findings warrant further investigation of dopamine signaling in conversion to exudative AMD.

多巴胺拮抗剂与向渗出性老年性黄斑变性转变增加之间的可能关联。
目的:研究多巴胺信号的调节是否影响向渗出性年龄相关性黄斑变性(AMD)的转变。方法:使用Duke Epic数据库进行回顾性队列研究。诊断为非渗出性AMD的患者至少随访1年,评估其眼睛是否转化为渗出性AMD。对诊断为AMD的眼睛进行年龄、性别、吸烟史、高血压、年龄相关性眼病研究(AREDS)或AREDS2处方、多巴胺调节治疗处方和多巴胺调节治疗适应症的评估。使用广义估计方程来计算从非渗出性AMD到渗出性AMD转换的个体变量的比值比。结果:354例初始诊断为非渗出性黄斑变性的患者中558只眼被评估为渗出性黄斑变性。在接受多巴胺拮抗剂治疗至少3年的患者中,向渗出性AMD的转化明显高于未接受任何多巴胺调节治疗的患者。在控制了其他变量后,多巴胺拮抗剂与3年随访时转化为渗出性AMD的风险增加相关(P = 0.005)。结论:这些研究结果表明,拮抗多巴胺信号可能与非渗出性黄斑变性眼部黄斑新生血管的形成有关。虽然这些数据是观察性的,但这些发现为进一步研究多巴胺信号在向渗出性AMD转化中的作用提供了依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
16.70%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信